Mary P. Moore - Concepedia

Author

Mary P. Moore

University of Missouri ORCID

Also Known As

MARY P. MOORE, Mary Moore, Mary P. Moore, Moore, Mary Patricia

Publications

516

Citations

H-Index

Concepts

All Affiliations

University of Missouri Harry S. Truman Memorial Veterans' Hospital Professional Services Group (United States)Columbia University Irving Medical Center

About

Mary P. Moore is an author at University of Missouri specializing in medicine, metabolic syndrome, and diabetes.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	48
2	Health Sciences	1	1	34
3	Diabetes	1	1	34
4	Exercise Physiology	1	1	34
5	Kinesiology	1	1	34

Mary P. Moore

Publications

368

Citations

H-Index

Page 1

	Year	Citations
Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD Mary P. Moore, Rory P. Cunningham, Grace M. Meers, Hepatology	2022	212
Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH Justine M. Mucinski, Amadeo F. Salvador, Mary P. Moore, Journal of Hepatology Insulin ResistanceMetabolic SyndromeEnergy HomeostasisBody CompositionKinesiology	2024	34
Critical Role for Hepatocyte-Specific eNOS in NAFLD and NASH Rory P. Cunningham, Mary P. Moore, Ryan J. Dashek, Diabetes	2021	26
A dietary ketone ester mitigates histological outcomes of NAFLD and markers of fibrosis in high-fat diet fed mice Mary P. Moore, Rory P. Cunningham, Rachel Davis, American Journal of Physiology-Gastrointestinal and Liver Physiology	2021	22
Relationship between serum β-hydroxybutyrate and hepatic fatty acid oxidation in individuals with obesity and NAFLD Mary P. Moore, Grace Shryack, Isabella Alessi, American Journal of Physiology-Endocrinology and Metabolism	2024	22
A warning to clinicians: metronidazole neurotoxicity in a dog R. Holly Fitch, Mary P. Moore, Diana Roen Metronidazole NeurotoxicityMedicineVeterinary ScienceSmall Animal Internal MedicineToxicology	1991	14
Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers Xiaobo Wang, Mary P. Moore, Hongxue Shi, Molecular Therapy — Methods & Clinical Development	2023	14
Low MBOAT7 expression, a genetic risk for MASH, promotes a profibrotic pathway involving hepatocyte TAZ upregulation Mary P. Moore, Xiaobo Wang, John P. Kennelly, Hepatology	2024	14
Isotope Labeling and Biochemical Assessment of Liver-Triacylglycerol in Patients with Different Levels of Histologically-Graded Liver Disease Majid Mufaqam Syed‐Abdul, Mary P. Moore, Andrew A. Wheeler, Journal of Nutrition	2023	10

Page 1